Heparin is not a low molecular weight heparin
I'm thinking that the 5000 you are referring to is 5000 units because 5000 units administered subcutaneously two or three times daily as a pretty standard dose for preventing blood clots with heparin
Pharmacy student
heparin/low molecular weight heparin
the half life of heparin is 2 hours and that of low molecular weight heparin (LMWH) is 4 hours
Standard heparin, an effective treatment for antepartum thromboembolic disease, is thought to be safe for the fetus since it does not cross the placenta. Recently, a number of low molecular weight heparins have been prepared which have been shown to produce less bleeding than standard heparin for an equivalent antithrombotic effect in experimental animals. These observations suggest that the low molecular weight heparins may also provide superior antithrombotic therapy in antepartum thromboembolic disease. However, it is not known whether the low molecular weight heparins cross the placenta. To determine this, we examined the pharmacokinetics of 125I-labelled standard heparin and a low molecular weight heparin, and their anticoagulant effects in mother and fetus, using a pregnant sheep model. Catheters were inserted into maternal and fetal femoral arteries at 108-119 d gestation (term: 147 d). 1-3 days later the mothers were given a bolus i.v. injection of 5000 anti-Xa units of 125I-labelled standard heparin or low molecular weight heparin, CY 222. Nine serial blood samples were collected over 4 h from both mother and fetus for measurements of radioactivity, anti-Xa activity (chromogenic) and activated partial thromboplastin times. When therapeutic levels of standard and CY 222 heparins were achieved in the mother, there was no detectable radioactivity or anticoagulant effect in the fetus. We conclude that standard heparin and the low molecular weight CY 222 do not cross the placenta in the pregnant sheep.
Trevor David Power has written: 'Derivatization of low molecular weight heparin with polyethylene glycol monomethyl ether (MPEG)' -- subject(s): Heparin, Chemistry, Methyl ether
Enoxaparin was developed by the Sanofi-Aventis company. It was patented in 1987 and approved for medical use in 1993. Enoxaparin is a low molecular weight heparin that is used as an anticoagulant to prevent blood clot formation.
This is a catalyst.
There are two main types of heparin: unfractionated heparin (UFH) and low molecular weight heparin (LMWH). UFH is more effective in treating acute conditions but requires close monitoring due to its higher risk of side effects like bleeding. LMWH is easier to use and has a lower risk of side effects, making it a preferred choice for long-term treatment.
The density of low molecular weight polyisobutylene (PIB) typically ranges from 0.87 to 0.92 g/cm3. The exact value may vary based on factors such as molecular weight and purity of the material. It is a generally low-density material.
Fragmin/Heparin a low-molecular-weight heparin is a new DVT treatment. It's effective within hours, reducing complications and hospitalizations. You can do the injections at home, once or twice daily, on an outpatient basis. And because it is more consistent and predictable, it doesn't require regular blood tests. Also the duration of action of a single dose of warfarin is 2 to 5 days.
The absolute value of molecular weight (molar mass) is somewhat arbitrary. It's like asking if 100 is a large number, small number or somewhere in between. There are molecular weights as low as, say 2 g/mole for H2 gas, and as high as several thousand for a protein or other polymer. So, a molecular weight of 84 is high compared to a MW of 2, but is low compared to a MW of 100,000.
yes, Dextrins are a group of low-molecular-weight carbohydrates produced by the hydrolysis of starch or glycogen.
The molecular formula of Sweet'N Low, an artificial sweetener, is C14H19N3O2.